{"id":2202,"date":"2026-04-10T08:27:38","date_gmt":"2026-04-10T05:27:38","guid":{"rendered":"https:\/\/merkezlaboratuvari.com\/test-listesi\/ck-mb-2\/"},"modified":"2026-04-21T12:38:55","modified_gmt":"2026-04-21T09:38:55","slug":"ck-mb","status":"publish","type":"page","link":"https:\/\/merkezlaboratuvari.com\/ar\/test-listesi\/ck-mb\/","title":{"rendered":"CK-MB"},"content":{"rendered":"<h1>CK-MB<\/h1>\n<h2>Laboratuvar Bilgileri<\/h2>\n<ul>\n<li><strong>Yeni Kod:<\/strong> BIO9540<\/li>\n<li><strong>SUT Kodu:<\/strong> L104760<\/li>\n<li><strong>Eski Kod:<\/strong> B\u01300058<\/li>\n<li><strong>Kategori:<\/strong> \u0643\u064a\u0645\u064a\u0627\u0621 \u062d\u064a\u0648\u064a\u0629<\/li>\n<li><strong>Numune T\u00fcr\u00fc:<\/strong> Serum<\/li>\n<li><strong>Numune Kab\u0131:<\/strong> Sar\u0131 Kapak<\/li>\n<li><strong>\u00c7al\u0131\u015fma G\u00fcn\u00fc:<\/strong> Her g\u00fcn<\/li>\n<li><strong>\u00d6nemli Kriter:<\/strong> \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.<\/li>\n<li><strong>Raporlama Tarihi:<\/strong> Ayn\u0131 g\u00fcn 18:00<\/li>\n<\/ul>\n<h2>CK-MB Testi Nedir?<\/h2>\n<p>CK-MB, laboratuvar ortam\u0131nda de\u011ferlendirilen bir biyokimya testidir. De\u011ferlendirme \u00e7o\u011fu zaman serum \u00f6rne\u011fi \u00fczerinden planlan\u0131r.<\/p>\n<p>CK-MB, kreatin kinaz enziminin kalp kas\u0131nda bask\u0131n olan izoenzimidir. Miyokard hasar\u0131 olu\u015ftu\u011funda kana sal\u0131n\u0131r. Akut miyokard enfarkt\u00fcs\u00fcn\u00fcn (AMI) tan\u0131s\u0131nda ve reinfarkt\u00fcs de\u011ferlendirmesinde kullan\u0131l\u0131r. G\u00fcn\u00fcm\u00fczde troponin testleri AMI tan\u0131s\u0131nda \u00f6ncelikli belirte\u00e7tir; ancak CK-MB halen reinfarkt\u00fcs tespitinde ve miyokard hasar\u0131n\u0131n zamanlamas\u0131nda de\u011ferli bilgi sa\u011flar.<\/p>\n<p>Bu testin klinik anlam\u0131; istem nedeni, hastan\u0131n yak\u0131nmalar\u0131, ya\u015f\u0131, e\u015flik eden hastal\u0131klar\u0131, kullan\u0131lan y\u00f6ntem ve di\u011fer laboratuvar bulgular\u0131 ile birlikte de\u011ferlendirilir. Bu nedenle sonu\u00e7, tek ba\u015f\u0131na de\u011fil, b\u00fct\u00fcnc\u00fcl t\u0131bbi \u00e7er\u00e7eve i\u00e7inde yorumlanmal\u0131d\u0131r.<\/p>\n<h2>CK-MB Hangi Durumlarda \u0130stenir?<\/h2>\n<p>CK-MB testi, hekim taraf\u0131ndan klinik gereklilik g\u00f6r\u00fclen durumlarda istenebilir. \u0130stem gerek\u00e7esi hastan\u0131n mevcut tablosuna g\u00f6re de\u011fi\u015febilir.<\/p>\n<ul>\n<li>Akut miyokard enfarkt\u00fcs\u00fc tan\u0131s\u0131 (troponin ile birlikte)<\/li>\n<li>Reinfarkt\u00fcs (yeniden enfarkt\u00fcs) \u015f\u00fcphesi<\/li>\n<li>Miyokard hasar\u0131n\u0131n zamanlamas\u0131n\u0131n belirlenmesi<\/li>\n<li>Kardiyak cerrahi sonras\u0131 miyokard hasar\u0131 takibi<\/li>\n<li>Miyokardit de\u011ferlendirmesi<\/li>\n<li>G\u00f6\u011f\u00fcs a\u011fr\u0131s\u0131n\u0131n ay\u0131r\u0131c\u0131 tan\u0131s\u0131<\/li>\n<li>Total CK y\u00fcksekli\u011finin kardiyak k\u00f6kenli olup olmad\u0131\u011f\u0131n\u0131n belirlenmesi<\/li>\n<\/ul>\n<p>Ayn\u0131 test farkl\u0131 hastalarda farkl\u0131 klinik sorulara yan\u0131t aramak amac\u0131yla kullan\u0131labildi\u011fi i\u00e7in, nihai de\u011ferlendirme her zaman ki\u015fisel t\u0131bbi \u00f6yk\u00fc ve muayene bulgular\u0131 ile birlikte yap\u0131lmal\u0131d\u0131r.<\/p>\n<h2>CK-MB Testi \u00d6ncesi Haz\u0131rl\u0131k<\/h2>\n<p>Haz\u0131rl\u0131k gereksinimi; testin t\u00fcr\u00fcne, numune yap\u0131s\u0131na ve laboratuvar\u0131n \u00e7al\u0131\u015fma kurallar\u0131na g\u00f6re de\u011fi\u015febilir. Test \u00f6ncesinde laboratuvar\u0131n ve hekimin verdi\u011fi talimatlar esas al\u0131nmal\u0131d\u0131r.<\/p>\n<ul>\n<li>A\u00e7l\u0131k gerekmez.<\/li>\n<li>A\u011f\u0131r fiziksel aktiviteden ka\u00e7\u0131n\u0131lmal\u0131d\u0131r.<\/li>\n<li>\u0130ntram\u00fcsk\u00fcler enjeksiyonlardan ka\u00e7\u0131n\u0131lmal\u0131d\u0131r.<\/li>\n<\/ul>\n<p>Kullan\u0131lan ila\u00e7lar, takviyeler, yak\u0131n d\u00f6nemde ge\u00e7irilen hastal\u0131klar ve e\u015flik eden kronik durumlar sonucun yorumlanmas\u0131n\u0131 etkileyebilece\u011fi i\u00e7in sa\u011fl\u0131k profesyoneli ile payla\u015f\u0131lmal\u0131d\u0131r.<\/p>\n<h2>CK-MB Testi Nas\u0131l Yap\u0131l\u0131r?<\/h2>\n<p>CK-MB testi, uygun biyolojik \u00f6rnek al\u0131nd\u0131ktan sonra laboratuvar\u0131n belirledi\u011fi y\u00f6ntemle \u00e7al\u0131\u015f\u0131l\u0131r. Numunenin do\u011fru zamanda, uygun kapta ve uygun ta\u015f\u0131ma ko\u015fullar\u0131nda ula\u015ft\u0131r\u0131lmas\u0131 test kalitesi a\u00e7\u0131s\u0131ndan \u00f6nem ta\u015f\u0131r.<\/p>\n<ul>\n<li><strong>Numune tipi:<\/strong> Ven\u00f6z kan (serum)<\/li>\n<li><strong>Numune al\u0131m\u0131:<\/strong> Koldan ven\u00f6z kan al\u0131n\u0131r.<\/li>\n<li><strong>Y\u00f6ntem:<\/strong> \u0130mm\u00fcnoinhibisyon y\u00f6ntemi (CK-MB aktivite) veya imm\u00fcnoassay (CK-MB mass)<\/li>\n<li><strong>CK-MB mass:<\/strong> Daha spesifik; ng\/mL olarak raporlan\u0131r.<\/li>\n<li><strong>Sonu\u00e7 s\u00fcresi:<\/strong> Acil durumlarda 1\u20132 saat; rutin ayn\u0131 g\u00fcn.<\/li>\n<\/ul>\n<p>Baz\u0131 durumlarda \u00f6rnek kalitesi, numune miktar\u0131, ta\u015f\u0131ma s\u00fcresi veya teknik tekrar gereksinimi raporlama s\u00fcresini ve sonucun g\u00fcvenilirli\u011fini etkileyebilir.<\/p>\n<h2>CK-MB Testi Ka\u00e7 G\u00fcnde \u00c7\u0131kar?<\/h2>\n<p>Mevcut laboratuvar bilgisine g\u00f6re bu test i\u00e7in raporlama s\u00fcresi: <strong>Ayn\u0131 g\u00fcn 18:00<\/strong> \u015feklindedir.<\/p>\n<p>Numunenin kabul zaman\u0131, laboratuvar\u0131n \u00e7al\u0131\u015fma plan\u0131, resmi tatiller veya gerekti\u011finde tekrar \u00e7al\u0131\u015fma gibi etkenler sonucu etkileyebilece\u011fi i\u00e7in en g\u00fcncel bilgi rapor tarihi \u00fczerinden de\u011ferlendirilmelidir.<\/p>\n<h2>Referans De\u011ferleri ve Sonu\u00e7lar\u0131n De\u011ferlendirilmesi<\/h2>\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parametre<\/th><th>De\u011fer Aral\u0131\u011f\u0131<\/th><\/tr><\/thead><tbody><tr><td>CK-MB mass<\/td><td>0\u20135 ng\/mL<\/td><\/tr><tr><td>CK-MB aktivite<\/td><td>0\u201325 U\/L<\/td><\/tr><tr><td>CK-MB \/ Total CK oran\u0131 (relatif indeks)<\/td><td><%5 (normal)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<p>> Not: CK-MB \/ Total CK oran\u0131 >%5 ise kardiyak kaynak d\u00fc\u015f\u00fcn\u00fcl\u00fcr.<\/p>\n<p>Referans bilgileri; kullan\u0131lan y\u00f6ntem, ya\u015f grubu, biyolojik \u00f6rnek tipi ve laboratuvar standard\u0131na g\u00f6re de\u011fi\u015febilece\u011finden, rapor \u00fczerinde yer alan laboratuvar yorumu esas al\u0131nmal\u0131d\u0131r.<\/p>\n<h2>CK-MB Sonucu Nas\u0131l Yorumlan\u0131r?<\/h2>\n<p>Test sonucu tek ba\u015f\u0131na kesin tan\u0131 koydurmaz. Sonu\u00e7; klinik bulgular, di\u011fer laboratuvar verileri ve gerekli g\u00f6r\u00fcld\u00fc\u011f\u00fcnde ek incelemeler ile birlikte de\u011ferlendirilir.<\/p>\n<h3>Y\u00fcksek CK-MB<\/h3>\n<p><strong>Kardiyak nedenler:<\/strong><\/p>\n<ul>\n<li>Akut miyokard enfarkt\u00fcs\u00fc<\/li>\n<li>Reinfarkt\u00fcs<\/li>\n<li>Miyokardit<\/li>\n<li>Kardiyak cerrahi (CABG, kapak cerrahisi)<\/li>\n<li>Kardiyoversiyon \/ defibrilasyon<\/li>\n<li>Kardiyak kateterizasyon komplikasyonu<\/li>\n<li>Kalp kont\u00fczyonu (k\u00fcnt g\u00f6\u011f\u00fcs travmas\u0131)<\/li>\n<\/ul>\n<p><strong>Kardiyak d\u0131\u015f\u0131 nedenler (daha az belirgin):<\/strong><\/p>\n<ul>\n<li>Rabdomiyoliz (iskelet kas\u0131nda da az miktarda CK-MB bulunur)<\/li>\n<li>A\u011f\u0131r egzersiz (maratoncular)<\/li>\n<li>M\u00fcsk\u00fcler distrofi<\/li>\n<li>Polimiyozit<\/li>\n<li>B\u00f6brek yetmezli\u011fi<\/li>\n<li>Hipotiroidizm<\/li>\n<\/ul>\n<h3>CK-MB Kinetik Profili (AMI)<\/h3>\n<ul>\n<li>Y\u00fckselme ba\u015flang\u0131c\u0131: 3\u20136 saat<\/li>\n<li>Pik zaman\u0131: 12\u201324 saat<\/li>\n<li>Normale d\u00f6n\u00fc\u015f: 48\u201372 saat<\/li>\n<\/ul>\n<h3>Relatif \u0130ndeks (CK-MB \/ Total CK \u00d7 100)<\/h3>\n<ul>\n<li><strong>>%5:<\/strong> Kardiyak kaynakl\u0131 hasar<\/li>\n<li><strong><%5:<\/strong> \u0130skelet kas\u0131 kaynakl\u0131 (egzersiz, travma, miyopati)<\/li>\n<\/ul>\n<h3>Reinfarkt\u00fcs De\u011ferlendirmesi<\/h3>\n<ul>\n<li>CK-MB normale d\u00f6nd\u00fckten sonra tekrar y\u00fckselmesi reinfarkt\u00fcs\u00fc d\u00fc\u015f\u00fcnd\u00fcr\u00fcr.<\/li>\n<li>Troponin uzun s\u00fcre y\u00fcksek kald\u0131\u011f\u0131ndan reinfarkt\u00fcs tespitinde CK-MB daha avantajl\u0131d\u0131r.<\/li>\n<\/ul>\n<p>\u00d6zellikle s\u0131n\u0131rda, d\u00fc\u015f\u00fck d\u00fczeyli veya beklenmeyen sonu\u00e7larda klinik korelasyon gerekir. Gerekti\u011finde tekrar test, panel de\u011ferlendirmesi veya ek laboratuvar incelemeleri planlanabilir.<\/p>\n<h2>Testin S\u0131n\u0131rl\u0131l\u0131klar\u0131<\/h2>\n<p>Her laboratuvar testinde oldu\u011fu gibi bu incelemenin de baz\u0131 s\u0131n\u0131rl\u0131l\u0131klar\u0131 vard\u0131r. Sonu\u00e7; \u00f6rnek kalitesi, \u00f6rnekleme zaman\u0131, ta\u015f\u0131ma ko\u015fullar\u0131 ve klinik ba\u011flamdan etkilenebilir.<\/p>\n<ul>\n<li>Tek bir laboratuvar sonucu, klinik \u00e7er\u00e7eve d\u0131\u015f\u0131nda eksik yorumlanabilir.<\/li>\n<li>Uygun olmayan numune kalitesi sonucun g\u00fcvenilirli\u011fini azaltabilir.<\/li>\n<li>Gerekti\u011finde ek testler olmadan tek ba\u015f\u0131na karar vermek yan\u0131lt\u0131c\u0131 olabilir.<\/li>\n<\/ul>\n<h2>Olas\u0131 Riskler<\/h2>\n<p>Risk \u00e7o\u011funlukla numune alma ve numune y\u00f6netimi s\u00fcreci ile ili\u015fkilidir. Testin kendisinden \u00e7ok, \u00f6rne\u011fin al\u0131nmas\u0131 ve uygun ko\u015fullarda \u00e7al\u0131\u015f\u0131lmas\u0131 \u00f6nem ta\u015f\u0131r.<\/p>\n<ul>\n<li>G\u00fcn\u00fcm\u00fczde y\u00fcksek duyarl\u0131l\u0131kl\u0131 troponin (hs-Troponin) AMI tan\u0131s\u0131nda birincil belirte\u00e7tir; CK-MB tamamlay\u0131c\u0131 olarak kullan\u0131l\u0131r.<\/li>\n<li>CK-MB, troponine g\u00f6re daha erken normale d\u00f6ner; bu \u00f6zellik reinfarkt\u00fcs tan\u0131s\u0131nda avantaj sa\u011flar.<\/li>\n<li>\u0130skelet kas\u0131 hasar\u0131nda da CK-MB artabilir; relatif indeks ile ayr\u0131m yap\u0131lmal\u0131d\u0131r.<\/li>\n<li>CK-MB mass y\u00f6ntemi, CK-MB aktivite y\u00f6ntemine g\u00f6re daha spesifik ve duyarl\u0131d\u0131r.<\/li>\n<li>Makro-CK varl\u0131\u011f\u0131nda (CK-BB veya mitokondriyal CK imm\u00fcnoglobuline ba\u011flanmas\u0131) yanl\u0131\u015f y\u00fcksek CK-MB aktivite sonu\u00e7lar\u0131 g\u00f6r\u00fclebilir.<\/li>\n<li>Kardiyak cerrahi sonras\u0131 CK-MB y\u00fcksekli\u011fi beklenir; perioperatif MI tan\u0131s\u0131 i\u00e7in e\u015fik de\u011ferler farkl\u0131d\u0131r.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>CK-MB Laboratuvar Bilgileri Yeni Kod: BIO9540 SUT Kodu: L104760 Eski Kod: B\u01300058 Kategori: Biyokimya Numune T\u00fcr\u00fc: Serum Numune Kab\u0131: Sar\u0131 Kapak \u00c7al\u0131\u015fma G\u00fcn\u00fc: Her g\u00fcn \u00d6nemli Kriter: \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r. Raporlama Tarihi: Ayn\u0131 g\u00fcn 18:00 CK-MB Testi Nedir? CK-MB, laboratuvar ortam\u0131nda de\u011ferlendirilen bir biyokimya testidir. De\u011ferlendirme [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":5,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"test_category":"Biyokimya","test_kodu":"BIO9540","numune_turu":"Serum","numune_kabi":"Sar\u0131 Kapak","calisma_gunu":"Her g\u00fcn","onemli_kriter":"\u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.","raporlama_tarihi":"Ayn\u0131 g\u00fcn 18:00","numune_red_kriterleri":"","aktarim_kodu":"","loinc_kodu":"","sut_kodu":"L104760","akredite":"","numune_miktari":"","alternatif_ornek":"","numune_alinma_sekli":"","stabilite_ozellikleri":"","calisma_yontemi":"","test_bilgisi":"","footnotes":""},"class_list":["post-2202","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/2202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/comments?post=2202"}],"version-history":[{"count":4,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/2202\/revisions"}],"predecessor-version":[{"id":9069,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/2202\/revisions\/9069"}],"up":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/5"}],"wp:attachment":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/media?parent=2202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}